Security
Jupiter Neurosciences, Inc. Common Stock · JUNS
JUNSNASDAQCommon stockCurrentCIK 1679628Updated Oct 27, 2026
Name history
Jupiter Orphan Therapeutics, Inc. · through Dec 5, 2017
JUNS price & chart
Loading TradingView…
NASDAQ:JUNS on TradingView ↗In the news
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million ↗
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million ↗
Recent filings
S-8 filing
S-3 filing
SCHEDULE 13G - filed by PharmAla Biotech Holdings Inc. regarding JUPITER NEUROSCIENCES, INC.
D filing
Items 06b
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
Show 5 more recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 1.01, 5.02, 8.01, 9.01
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
424B5 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 2,576,259Source | 85,546Source | 3,718,600Source | 3,968,103Source | — | 3,948,584Source | 4,962,826Source | — | 5,564,030Source | 6,202,409Source | 148,592Source |
| Current assets: | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 10,241Source | — | — | — | — | — | 2,637Source | — | — |
| Inventory, NetUSD | — | — | 135,290Source | — | — | 148,068Source | — | — | 159,790Source | — | — |
| Assets, CurrentUSD | 1,632,358Source | 514Source | 2,548,806Source | 2,819,132Source | — | 3,410,180Source | 3,611,328Source | — | 4,824,978Source | 4,650,263Source | 28,739Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | — | 114,086Source | 261Source |
| Operating Lease, Right-of-Use AssetUSD | 34,821Source | 81,249Source | 219,864Source | 46,649Source | — | 11,607Source | 58,035Source | — | 23,214Source | 69,642Source | 116,070Source |
| Other Assets, NoncurrentUSD | 3,783Source | 3,783Source | 618,058Source | 3,783Source | — | 3,783Source | 3,783Source | — | 3,783Source | 3,783Source | 3,783Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 2,518,842Source | 5,836,542Source | 4,084,566Source | 2,627,985Source | — | 6,732,041Source | 1,898,231Source | — | 7,395,882Source | 2,030,401Source | 5,949,946Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 3,429Source | 3,012Source | 66Source | 3,483Source | — | 3,628Source | 3,310Source | — | 3,444Source | 3,310Source | 2,652Source |
| Additional Paid in CapitalUSD | 32,145,983Source | 18,815,494Source | 38,637,349Source | 31,140,596Source | — | 33,941,899Source | 30,612,281Source | — | 32,831,730Source | 30,190,827Source | 17,778,498Source |
| Retained Earnings (Accumulated Deficit)USD | -32,091,995Source | -24,494,502Source | -39,003,381Source | -29,803,961Source | — | -36,728,984Source | -27,550,996Source | — | -34,667,026Source | -26,022,129Source | -23,582,504Source |
| Stockholders' Equity Attributable to ParentUSD | 57,417Source | -5,750,996Source | -365,966Source | 1,340,118Source | -5,355,031Source | -2,783,457Source | 3,064,595Source | -6,020,137Source | -1,831,852Source | 4,172,008Source | -5,801,354Source |
| Liabilities and EquityUSD | 2,576,259Source | 85,546Source | 3,718,600Source | 3,968,103Source | — | 3,948,584Source | 4,962,826Source | — | 5,564,030Source | 6,202,409Source | 148,592Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 2,518,842Source | 5,680,856Source | 3,879,498Source | 2,627,985Source | — | 6,732,041Source | 1,889,724Source | — | 7,395,882Source | 2,009,154Source | 5,771,905Source |
| Operating Lease, Liability, CurrentUSD | 33,961Source | 49,609Source | 15,539Source | 46,428Source | — | 8,508Source | 50,556Source | — | 21,247Source | 50,082Source | 48,213Source |
| Operating Lease, Liability, NoncurrentUSD | — | 33,961Source | 205,068Source | — | — | — | 8,507Source | — | — | 21,247Source | 71,329Source |
| Deferred Revenue, Current | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 500,992Source | 421,454Source | 2,418,516Source | 1,840,908Source | 1,198,579Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -2,637Source | — | 2,637Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -11,722Source | — | 159,790Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,432,100Source | -1,063,041Source | -5,413,736Source | -3,911,004Source | -480,953Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 5,507Source | — | 5,433,568Source | 7,652,036Source | 445,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,426,593Source | -1,063,041Source | 19,832Source | 3,741,032Source | -35,953Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 146Source | — | 147,776Source | 28,128Source |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 500,992Source | — | — | 114,373Source | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | 549,098Source | — | 1,282Source | — | 281,932Source | — | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | 9,885Source | — | — | — | — | — | -53,257Source | 148,751Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 857,723Source | -887,946Source |
| General and Administrative ExpenseUSD | — | — | 1,480,356Source | 401,636Source | 2,163,656Source | 1,505,432Source | 1,566,241Source | 1,071,258Source | 6,839,712Source | 2,598,622Source | 2,915,978Source |
| InterestExpenseNonoperatingUSD | — | — | 1,193Source | 107,382Source | 90,618Source | 1,135Source | 118,644Source | 1,229Source | 66,020Source | 248,366Source | 218,705Source |
| Investment Income, InterestUSD | — | — | 10,212Source | 23Source | 10,068Source | 13,050Source | 18,404Source | 10,365Source | — | 5,557Source | 482Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,288,034Source | -591,021Source | -2,274,397Source | -2,252,965Source | -2,061,958Source | -1,528,867Source | -8,644,897Source | -2,439,625Source | -4,783,689Source |
| Nonoperating Income (Expense)USD | — | — | 9,019Source | -97,474Source | 468,548Source | 11,915Source | -98,958Source | 9,136Source | 263,824Source | 651,657Source | -912,918Source |
| Operating ExpensesUSD | — | — | 2,297,053Source | 493,547Source | 2,764,009Source | 2,264,880Source | 1,977,290Source | 1,538,003Source | 8,926,286Source | 3,091,282Source | 3,870,771Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 150,000Source | 55,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | 24,245Source | — | 18,652Source | 0Source | 21,796Source | — | — |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | 697,835Source | 355,829Source | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | — | — | —Source | — | — | — | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 24,245Source | — | 18,652Source | — | 21,796Source | — | — |
| Cost of RevenueUSD | — | — | — | — | 3,181Source | — | 4,362Source | — | 4,231Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | 2,163,656Source | — | 1,566,241Source | — | 6,839,712Source | — | — |
| Operating Income (Loss)USD | — | — | -2,297,053Source | -493,547Source | -2,742,945Source | -2,264,880Source | -1,963,000Source | -1,538,003Source | -8,908,721Source | -3,091,282Source | -3,870,771Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,288,034Source | -591,021Source | -2,274,397Source | -2,252,965Source | -2,061,958Source | -1,528,867Source | -8,644,897Source | -2,439,625Source | -4,783,689Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.07Source | -0.02Source | -4.08Source | -5.09Source | -0.06Source | -0.05Source | -0.25Source | -0.08Source | -0.18Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.07Source | -0.02Source | -4.08Source | -5.09Source | -0.06Source | -0.05Source | -0.25Source | -0.08Source | -0.18Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 34,039,906Source | 31,065,688Source | 557,567Source | 442,413Source | 35,255,588Source | 33,103,860Source | 34,628,588Source | 28,783,045Source | 26,405,109Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 34,039,906Source | 31,065,688Source | 557,567Source | 442,413Source | 35,255,588Source | 33,103,860Source | 34,628,588Source | 28,783,045Source | 26,405,109Source |
| Interest Expense (non-operating)USD | — | — | 1,193Source | 107,382Source | 90,618Source | 1,135Source | 118,644Source | 1,229Source | 66,020Source | 248,366Source | 218,705Source |
| Additional Financial Items | |||||||||||
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | — | 9,885Source | — | — | — | — | — | -53,257Source | 148,751Source |
| General and Administrative ExpenseUSD | — | — | 1,480,356Source | 401,636Source | 2,163,656Source | 1,505,432Source | 1,566,241Source | 1,071,258Source | 6,839,712Source | 2,598,622Source | 2,915,978Source |
| Gross ProfitUSD | — | — | — | — | 21,064Source | — | 14,290Source | — | 17,565Source | — | — |
| Investment Income, InterestUSD | — | — | 10,212Source | 23Source | 10,068Source | 13,050Source | 18,404Source | 10,365Source | — | 5,557Source | 482Source |
| Nonoperating Income (Expense)USD | — | — | 9,019Source | -97,474Source | 468,548Source | 11,915Source | -98,958Source | 9,136Source | 263,824Source | 651,657Source | -912,918Source |
| Operating ExpensesUSD | — | — | 2,297,053Source | 493,547Source | 2,764,009Source | 2,264,880Source | 1,977,290Source | 1,538,003Source | 8,926,286Source | 3,091,282Source | 3,870,771Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | 47,912Source | 90,000Source | 44,500Source |
| Research and Development ExpenseUSD | — | — | 816,697Source | 91,911Source | 600,353Source | 759,448Source | 411,049Source | 466,745Source | 2,086,574Source | 492,660Source | 954,793Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | — | — | 24,245Source | — | 18,652Source | 0Source | 21,796Source | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | — | — | —Source | — | — | — | — |
| Interest Expense, Debt | — | — | — | — | —Source | — | —Source | — | — | — | — |
Offerings
Registration 333-299124
Registration 333-297073
Registration 333-295085
Filing attachments
ex107.htm · S-8 · 2026-10-13
Calculation of Filing Fee Tables S-8 JUPITER NEUROSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ──────────────────────────────────────…
Read attachment ↗ex99-1.htm · S-8 · 2026-10-13
Exhibit 99.1 Jupiter Neurosciences, Inc. Amended and Restated 2025 Equity Incentive Plan Section 1. Establishment, Purpose and Duration 1.1 Establishment. Jupiter Neurosciences, Inc., a Delaware corporation, hereby establishes an incentive compensation plan to be known as the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan, as set forth in this document. This Plan permits the grant of various forms of equity- and cash-based awards. This Plan shall become effective upon shareholder app…
Read attachment ↗ex107.htm · S-3 · 2026-09-25
Calculation of Filing Fee Tables S-3 JUPITER NEUROSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate O…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-24
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering New York, August 21, 2026 - Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offerin…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-06
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Jupiter Neurosciences, Inc. Announces Reverse Stock Split Jupiter’s common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, August 5, 2026 /PRNewswire/ - Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and neurodegenerative disorders, today announced that the board of direct…
Read attachment ↗ex107.htm · S-1 · 2026-06-26
Calculation of Filing Fee Tables S-1 JUPITER NEUROSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr…
Read attachment ↗